NCT Number: NCT00000808
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
To determine the bioavailability, pharmacokinetics, and short-term safety and tolerance of nevirapine in HIV-1 infected pregnant women and their newborns when nevirapine is given to the mother during active labor, and when their neonates are dosed during the first week of life. To determine the short-term safety profile of mothers receiving zidovudine (AZT) who received nevirapine during active labor, and their neonates who received no dose, a single dose, or multiple doses of nevirapine and who are receiving AZT during the first 6 weeks of life.
Treatment of HIV-1 infected pregnant women during active labor may result in therapeutic levels of nevirapine in the neonate at the time of exposure to HIV-1 during parturition, decreasing the neonate's risk of infection.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year–60 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 1
Primary location
San Juan City Hosp, San Juan, Puerto Rico
About this study
Treatment of HIV-1 infected pregnant women during active labor may result in therapeutic levels of nevirapine in the neonate at the time of exposure to HIV-1 during parturition, decreasing the neonate's risk of infection.
Pregnant women in active labor receive single doses of oral nevirapine. The neonates of the first 4-6 (PER AMENDMENT 8/27/96, was 4) mothers receive no drug, while the neonates of the second 4-6 (PER AMENDMENT 8/27/96, was 4) patient cohort receive a single dose of nevirapine. If neonatal antiviral levels of nevirapine are not sustained for 7 days after the single dose, a third cohort of 4-6 (PER AMENDMENT 8/27/96, was 4) pregnant women will receive a single dose of nevirapine and their neonates will receive multiple doses of nevirapine to maintain an antiviral effect for 7 days.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Concurrent Medication:
Allowed:
- AZT (mothers and neonates).
- Oral asthma inhalers (mothers).
Concurrent Treatment:
Allowed:
- Phototherapy (neonates).
MOTHERS must have:
- HIV infection.
- Estimated gestational age >= 34 weeks.
- No active opportunistic infection at study entry.
PER AMENDMENT 8/27/96:
- A pre-enrollment plasma HIV-1 RNA level greater than 10,000 copies/ml.
Exclusion criteria
Co-existing Condition:
MOTHERS with the following symptoms or conditions are excluded:
- Intrauterine growth retardation.
- Fetal anomaly incompatible with life as determined by pre-entry ultrasound.
- Participation during current pregnancy in any other therapeutic or vaccine perinatal trial.
- Known hypersensitivity to any benzodiazepine.
- Serious bacterial infection.
Concurrent Medication:
Excluded:
- Any antiretroviral other than AZT.
- Corticosteroids (other than oral asthma inhalers).
- Anticoagulants.
- Any clavulanic acid-containing formulation (e.g., Augmentin, Timentin).
- Benzodiazepines other than study drug.
- Phenobarbital.
- Barbiturates.
- Antacids.
- Magnesium sulfate.
Prior Medication:
Excluded:
- Prior nevirapine.
Current use of illicit substances and/or active chronic alcohol use.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Registry information
Important dates
- Study completion
- 1998
- First posted
- Aug 31, 2001
- Registry last updated
- Nov 4, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women
NCT00000839
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Los Angeles, California, United States
View Trial DetailsA Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
NCT00000751
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
La Jolla, California, United States
View Trial DetailsStudy of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine
NCT00000828
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
Birmingham, Alabama, United States
View Trial DetailsA Study of Zidovudine in HIV-Infected Pregnant Women and Their Children
NCT00001106
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Los Angeles, California, United States
View Trial Details